Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.84 |
| ▸ | F2 | P00734 | 14/20 | 0.77 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.77 |
| ▸ | F9 | P00740 | 1/20 | 0.77 |
| ▸ | F10 | P00742 | 1/20 | 0.77 |
| ▸ | PLAT | P00750 | 1/20 | 0.77 |
| ▸ | F11 | P03951 | 1/20 | 0.77 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.77 |
| ▸ | F7 | P08709 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | F12 | P00748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643246 | 0.92 | CYP3A4 (1.00) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL642383 | 0.90 | CYP3A4 (0.82) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL642370 | 0.87 | F2 (1.00) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL642426 | 0.87 | F2 (1.00) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL642384 | 0.87 | F2 (1.00) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL641392 | 0.87 | F2 (0.88) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL643657 | 0.85 | F2 (0.77) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL641710 | 0.84 | CYP3A4 (0.76) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL642760 | 0.84 | CYP3A4 (0.60) | CYP3A4F2PRSS1F9F10 | |
| SCHEMBL643641 | 0.84 | CYP3A4 (0.80) | CYP3A4F2PRSS1F9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011525487-A | — | — | 2011-09-22 | — | — | JP | claimed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | claimed |
| EP-2321301-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| WO-2009157860-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2009-12-30 | — | — | WO | claimed |
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| EP-2321301-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009157860-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | TFPI, TFPI2, SPINT2 | CYP3A4 222/4885F2 19/4885PRSS1 4/4885 |
| US-20090318517-A1 | Novel Compounds 148 | SERPINB1, SPINT2, TFPI | CYP3A4 286/4885F2 32/4885PRSS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.